disease as well as increased mortality from cardiovascular disease and all causes. [2] [3] [4] Beyond CVD and type 2 diabetes, individuals with metabolic syndrome seemingly are susceptible to other conditions, notably polycystic ovary syndrome, fatty liver, cholesterol gallstones, asthma, sleep disturbances, and some forms of cancer. 5 Although there are divergent criteria for the identification of the MetS, they all tend to agree that the MetS core components include obesity, insulin resistance, dyslipidemia, and hypertension. 6 The first formal definition of the MetS was put forth in 1998 by the World Health Organization (WHO). 7 The European Group for the Study of Insulin Resistance (EGIR) published a separate set of criteria shortly thereafter. 8 In 2001, the NCEP: ATP III published a new set of criteria based on common clinical measurements: Waist circumference (WC), blood lipids, blood pressure, and fasting glucose Table-I. 9 The prevalence of the metabolic syndrome as defined by ATP III in our country is unknown. Because the implications of the metabolic syndrome for health care are substantial, we sought to establish the prevalence and pattern of this condition.
Materials & Methods:
1068 patients were enrolled for a period of six month (October' 04 -March' 05). NCEP ATP III 2001 criteria were used to diagnose metabolic syndrome in our cohort of population. Patients who had two criteria primarily were included for study. They were thoroughly interviewed as per the protocol and related investigations were done. Three criteria that fulfill the diagnosis of metabolic syndrome are: (i) Abdominal obesity (waist circumference), Men >102 cm (40inch); Women >88 cm (35 inch) (ii) Blood pressure, >130/ mm of Hg (iii) Fasting blood glucose >110 mg/ dl. All the patients included in this study were above 20 years of age. Patients were excluded who had co-morbidity like CRF, CHD, and taking steroid for some other diseases because that would influence the inclusion criteria of metabolic syndrome. Lipid profile estimation was done after 10 hours fasting by Human GmbH kit. Blood sugar estimation was done by Human Gumbo kit. Body weight measurement was done by standard weighing measuring machine. 
Results:
Out of 1068 cases 101 (9.4%) fulfilled three criteria of metabolic syndrome. 09 cases fulfilled only two criteria. 40 cases male & 70 cases female (M:F= 1:1.8). Mean age of patients with SD is 44.88 ± 12.28 ranging from the age of 20-68 years. With the increase in age number of patients increased (Fig.-1) . 61 patients (55%) are between 3rd and 4th decade of age. 50% patients were obese, 22% moderately obese, only 5% had severe obesity. 15% were over weight and 8% had normal body weight. Table-II shows the patient profile. 35 (38.5%) patients had DyHO, 25 (27.5%) patients had DDyH, 22 (24.2%) patients had DDyHO, 13 (14.3%) patients had DHO, 6 (6.6%) patients had DDyO, and 9 (9.9%) patients had other types (Table-III) . 13 The prevalence increased from 6.7% among participants aged 20 through 29 years to 43.5% and 42.0% for participants aged 60 through 69 years and aged at least 70 years, respectively. Mexican Americans had the highest age-adjusted prevalence of the metabolic syndrome (31.9%). The age-adjusted prevalence was similar for men (24.0%) and women (23.4%). However, among African Americans, women had about a 57% higher prevalence than men did and among Mexican Americans, women had about a 26% higher prevalence than men did. Using 2000 census data, about 47 million US residents have the metabolic syndrome. 13 In Finland and Sweden MetS prevalence was studied using WHO definition of MetS. A total of 4,483 subjects aged 35-70 years participating in a large family study of type 2 diabetes in Finland and Sweden (the Botnia study) were included in the analysis of cardiovascular risk associated with the metabolic syndrome. In subjects who had type 2 diabetes (n = 1,697), impaired fasting glucose (IFG)/impaired glucose tolerance (IGT) (n = 798), or insulin-resistance with normal glucose tolerance (NGT) (n = 1,988), the metabolic syndrome was defined as presence of at least two of the following risk factors: hypertension, dyslipidemia, or microalbuminuria. Cardiovascular mortality was assessed in 3,606 subjects with a median follow-up of 6.9 years. In women and men, respectively, the metabolic syndrome was seen in 10 and 15% of subjects with NGT, 42 and 64% of those with IFG/IGT, and 78 and 84% of those with type 2 diabetes. 14 The risk for coronary heart disease and stroke was increased threefold in subjects with the syndrome (p < 0.001). Cardiovascular mortality was markedly increased in subjects with the metabolic syndrome (12.0 vs. 2.2%, p < 0.001). Of the individual components of the metabolic syndrome, microalbuminuria conferred the strongest risk of cardiovascular death (RR 2.80; p = 0.002). 14 Changes in the characteristics of metabolic syndrome in South Korea was assessed between 1998 to 2001.Metabolic syndrome was defined according to NCEP ATP III criteria. The age-adjusted prevalence of metabolic syndrome was significantly higher in the 2001 survey than in 1998 survey (28.0 vs. 23.6%, P < 0.01). This represents an 18.6% increase in prevalence over 3 years (i.e., 6% per annum). 15 As because metabolic syndrome yet not have an universally acceptable definition for all ethnic class of population so prevalence and different modalities of presentation differs from different ethnic group in a same class for different criteria of definition at different time. To make an absolute conclusion and apprehension of risk of metabolic syndrome is a very difficult task.
Conclusion:
Metabolic syndrome is not only the problem for the affluent class and for the western countries only. It is a new hidden burden for the Bangladeshi population too. The prevalence of metabolic syndrome in our study is much lower than that of many other populations of the world. A larger population based study is required to find out the magnitude of metabolic syndrome in Bangladeshi population.
